OpenAI punted. Anthropic stalled. The hottest imminent IPO fits on your finger

Oura reported $1.2 billion in revenue for the nine months ended June 30, 2026, up from $697.6 million a year earlier, while net income rose to $60.8 million from $1.6 million. Its paid membership base reached 5.7 million at fiscal-year-end, representing 96% year-over-year growth, strengthening the case for its imminent IPO. Hardware accounts for roughly 80% of revenue, while Oura is positioning its 42 billion hours of health data and AI capabilities as a competitive moat, though data-privacy concerns remain a key risk.

Analysis

The key underwriting question is whether Oura can transition from a hardware-led revenue model into a durable consumer-health subscription platform before replacement-cycle demand normalizes. The reported profitability is encouraging, but investors should isolate subscription gross margin, paid-member churn, customer-acquisition cost and ring replacement cadence; a high hardware mix leaves earnings materially exposed to component costs, promotions and new-device launch timing. The most relevant public read-through is unfavorable for lower-priced trackers (GRMN) and potentially raises the bar for Apple (AAPL) and Samsung wearable engagement, rather than creating a direct near-term revenue threat to either ecosystem incumbent.

An IPO would likely command a scarcity premium as a scaled, profitable consumer-tech listing in a thin new-issue calendar. That premium can reverse quickly if the prospectus reveals slowing cohorts, subscription attach rates below expectations, or concentration in a small number of manufacturing partners; wearable hardware multiples compress sharply when growth falls below roughly 30% because the market reclassifies the business as discretionary electronics rather than recurring health software. Over the next 1-3 months, filing amendments on gross margin, paid-member retention and international mix matter more than the AI-data narrative, which is difficult to monetize absent regulated clinical products or enterprise partnerships.

The consensus may overvalue the claimed data moat. Consumer biometric data are only strategically valuable if Oura can convert them into demonstrably superior recommendations, lower churn, clinical validation or payer/provider revenue; privacy constraints may limit each pathway. Conversely, a credible medical-device clearance, payer reimbursement arrangement, or evidence that subscription retention improves through a weaker consumer-spending environment would justify a higher software-like multiple over the following 6-18 months.

Key Decisions for Investors

• No pre-IPO position: place OURA on the IPO watchlist and require disclosure of subscription ARR, gross retention/net retention, CAC payback and hardware gross margin before underwriting. Treat the first post-listing earnings report, not the IPO price, as the cleaner entry point.
• If OURA prices at a premium to mature consumer-hardware peers without separately disclosing subscription economics, avoid the first 30 trading days; consider a tactical short only after lock-up/borrow availability if quarterly revenue growth decelerates below 30% or gross margin contracts by more than 300 bps.
• Monitor GRMN relative to AAPL for a 1-3 month competitive signal: a sustained Oura-led premiumization cycle would be more damaging to GRMN's fitness/wellness positioning than to AAPL's bundled ecosystem. Do not initiate a pair until channel data show share loss or elevated promotional activity.
• Set thesis-falsification alerts around an FDA-cleared indication, a meaningful insurer/payer partnership, or subscription retention above 85% with expanding gross margin; any of these would support treating OURA as a healthcare-data platform rather than a discretionary wearable vendor.